Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

anacetrapib Articles

EMA starts review of Merck & Co's cholesterol drug Tredaptive

24 December 2012

Discontinuation of dalcetrapib leaves Merck's anacetrapib as the front-running novel CETP inhibitor for dyslipidemia

20 September 2012

Merck & Co to file for approval of two heart drugs next year

28 August 2012

US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion

27 August 2012

Merck & Co's Ph III cholesterol inhibitor anacetrapib meets safety and efficacy endpoints in patients with CHD

18 November 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS